BioSpace News Archive

March 2020 issue of AAC journal highlights in vitro study at MD Anderson Cancer Center Labs that shows Mino-Lok to be effective in completely eradicating all ten strains of Candida auris tested [26-March-2020] CRANFORD, N.J. , March 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focu

Annual Report, including the Sustainability Report, for the 2019 fiscal year has been published.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on recent developments.

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and full year ended December 31, 2019, as well as provided a business update on recent corporate and clinical developments.

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2019 and provides a business update.

TherapeuticsMD, Inc. provided an update on its operations in response to the continued spread of COVID-19 pandemic.

Astrotech Corporation, announced that it has closed its previously announced registered direct offering priced at-the-market of 354,000 shares of its common stock at a price of $5.00 per share for aggregate gross proceeds of $1.77 million.

Disclaimer: This press release and our findings are solely intended as information for the scientific community.

Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis.

C2 PHARMA s.a.r.l., a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient, Digoxin.